Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Alterations in Muscle Tone ll

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

International journal of molecular sciences·2026

Same author

Early Detection of Large Vessel Occlusions by Bilateral Carotid Pressure Monitoring: Blinded Observational Study.

Stroke·2025

Same author

Evaluation, Diagnosis, and Treatment of Sydenham Chorea: Consensus Guidelines.

Pediatrics·2025

Same author

Does Size Matter? Exploring the Impact of Acellular Dermal Matrix Dimensions on Complications in Immediate Breast Reconstruction.

Plastic and reconstructive surgery. Global open·2025

Same author

Impact of time in therapeutic range (TTR) within the first 72 h on prognosis in patients with pulmonary embolism treated with unfractionated heparin.

Journal of thrombosis and thrombolysis·2025

Same author

Rediscovering the carotid pulse: unlocking hidden insights in the era of AI-driven healthcare.

Frontiers in neurology·2025

Search research articles

Related Experiment Video

Updated: May 14, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Levodopa does not improve function in individuals with dystonic cerebral palsy.

Inna Pozin¹, Tali Bdolah-Abram, Hilla Ben-Pazi

¹1Pediatric Movement Disorders, Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

Journal of Child Neurology

|January 26, 2013

Summary

Levodopa did not improve upper limb function in individuals with cerebral palsy (CP). This randomized controlled trial found no benefits of levodopa treatment compared to placebo for CP patients with dystonia.

Keywords:

Quality Of Upper Extremity Skills Test dopamine dystonia

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 14, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

Neurology
Pediatric Rehabilitation
Movement Disorders

Background:

Levodopa is a primary treatment for dystonia.
The efficacy of levodopa in cerebral palsy (CP) remains uninvestigated.
Upper limb dysfunction is a common challenge in CP.

Purpose of the Study:

To assess the effect of levodopa on upper limb function in individuals with CP.
To determine if levodopa can improve functional performance in quadriplegic CP with upper limb dystonia.

Main Methods:

A randomized, double-blind, placebo-controlled, crossover study.
Nine participants with quadriplegic CP and upper limb dystonia were enrolled.
Functional assessments included the box-and-blocks test, 9-hole peg test, dynamometry, and Quality of Upper Extremity Skills Test.

Main Results:

Levodopa treatment did not yield significant improvements in upper limb functional performance compared to placebo.
No adverse side effects were reported during the study period.
The dosage used was 6.65 ± 1.66 mg/kg/d of levodopa.

Conclusions:

Levodopa is not effective in improving upper limb function for individuals with cerebral palsy and dystonia.
Further research may be needed to explore alternative treatments for upper limb dysfunction in CP.